Insider Selling: RxSight, Inc. (NASDAQ:RXST) Insider Sells 3,100 Shares of Stock

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,100 shares of the business’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $50.09, for a total transaction of $155,279.00. Following the transaction, the insider now owns 42,246 shares of the company’s stock, valued at $2,116,102.14. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Ilya Goldshleger also recently made the following trade(s):

• On Friday, October 11th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $50.19, for a total value of $155,589.00.
• On Tuesday, October 8th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $48.26, for a total value of $149,606.00.
• On Friday, October 4th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $48.01, for a total value of $148,831.00.
• On Monday, September 30th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.02, for a total transaction of $151,962.00.
• On Thursday, September 26th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $49.29, for a total transaction of $153,045.45.
• On Monday, September 23rd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $52.67, for a total transaction of $163,277.00.
• On Friday, September 20th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $53.19, for a total value of $164,889.00.
• On Monday, August 5th, Ilya Goldshleger sold 9,000 shares of RxSight stock. The shares were sold at an average price of $39.25, for a total value of $353,250.00.

RxSight Price Performance

Shares of RxSight stock opened at $50.03 on Friday. The company’s fifty day simple moving average is $52.13 and its two-hundred day simple moving average is $53.82. RxSight, Inc. has a 12-month low of $20.66 and a 12-month high of $66.54.

RxSight (NASDAQ:RXST) last announced its quarterly earnings results on Monday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.06. RxSight had a negative return on equity of 19.33% and a negative net margin of 31.92%. The company had revenue of $34.89 million for the quarter, compared to the consensus estimate of $32.33 million. During the same quarter in the previous year, the business earned ($0.40) EPS. RxSight’s revenue was up 67.6% compared to the same quarter last year. As a group, equities analysts forecast that RxSight, Inc. will post -0.81 EPS for the current fiscal year.

Institutional Trading of RxSight

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RXST. Marshall Wace LLP purchased a new position in RxSight during the 2nd quarter valued at $19,512,000. Driehaus Capital Management LLC boosted its stake in shares of RxSight by 74.9% during the 2nd quarter. Driehaus Capital Management LLC now owns 706,162 shares of the company’s stock valued at $42,490,000 after purchasing an additional 302,367 shares in the last quarter. Baillie Gifford & Co. increased its position in shares of RxSight by 438.8% during the second quarter. Baillie Gifford & Co. now owns 358,215 shares of the company’s stock valued at $21,554,000 after buying an additional 291,733 shares during the period. William Blair Investment Management LLC bought a new position in RxSight in the second quarter worth about $14,942,000. Finally, M&G Plc bought a new position in RxSight in the first quarter worth about $7,354,000. Hedge funds and other institutional investors own 78.78% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on RXST shares. Wells Fargo & Company reduced their price target on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Oppenheimer reduced their target price on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a report on Tuesday, August 6th. Needham & Company LLC reissued a “buy” rating and issued a $66.00 price target on shares of RxSight in a research note on Friday, September 13th. BTIG Research raised their price objective on RxSight from $72.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, July 15th. Finally, Stifel Nicolaus lowered their target price on RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, RxSight currently has a consensus rating of “Buy” and an average price target of $60.14.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.